Adalimumab for Crohn's disease in clinical practice at Mayo clinic: The first 118 patients

Inflammatory Bowel Disease, 04/05/2010

Adalimumab was both effective and well tolerated for the treatment of CD in this tertiary practice with a high prevalence of past infliximab exposure. This experience largely predates FDA approval of adalimumab for CD.

Print Article Summary Cat 2 CME Report